The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
In a strategic move to solidify its position at the intersection of advanced skincare and medical aesthetics, Waldencast plc has secured a significant regulatory milestone. The company announced that the U.S. Food and Drug Administration (FDA) has approved Obagi saypha ChIQ, an injectable hyaluronic acid gel. According to reports, this approval is a core component of Obagi Medical’s strategy to become a leader in the high-growth medical aesthetics sector.
This approval arrives as the medical aesthetics market continues to expand, with firms competing for share in the injectable space dominated by industry giants like AbbVie. By integrating injectable treatments with its existing skincare line, Waldencast aims to offer a comprehensive aesthetic platform. Per market data, FDA approvals are critical catalysts for valuation in the beauty and healthcare sectors due to the rigorous safety and efficacy standards required for US commercialization.
Sign in to access this content
Sign InRegarding market performance, WALD shares stood at $1.86 (at close June 12, 2026), having traded between a high of $1.91 and a low of $1.81. Investors are now shifting focus toward the commercial rollout of the product and its impact on upcoming quarterly earnings. Looking ahead, the market will monitor the U.S. CPI inflation data on June 10 as a gauge for consumer discretionary spending power in the luxury and medical beauty categories.